Search research articles
Contact Us
Filters
Showing results (1-10 of 38) with videos related to
Page
of 4
Sort By:
Oncoimmunology
|
May 4, 2016
IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?
Jakub Tomala, Marek Kovar
Methods in Molecular Biology (Clifton, N.J.)
|
January 15, 2020
Characterization of Immune Cell Subset Expansion in Response to Therapeutic Treatment in Mice
Jakub Tomala, Jamie B Spangler
Immunology Letters
|
February 12, 2014
Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera
Petra Votavova, Jakub Tomala, Marek Kovar
Journal of Immunology (Baltimore, Md. : 1950)
|
January 2, 2024
Engineering Anticytokine Antibodies for Immune Modulation
Jakub Tomala, Shanelle D Cao, Jamie B Spangler
Journal of Immunology (Baltimore, Md. : 1950)
|
October 6, 2009
In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy
Jakub Tomala, Helena Chmelova, Tomas Mrkvan, et al.
Cytokine
|
June 30, 2020
IL-7/αIL-7 mAb M25 immunocomplexes expand CD8<sup>+</sup> T cells but paradoxically abrogate the antitumor activity of CTLA-4 and PD-1 blockage
Dominik Hrabos, Tereza Hnizdilova, Jakub Tomala, et al.
Journal of Drug Targeting
|
October 11, 2011
Synergistic effect of EMF-BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma
Blanka Říhová, Tomáš Etrych, Milada Šírová, et al.
Oncoimmunology
|
June 23, 2017
Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells
Irena Adkins, Lenka Sadilkova, Nada Hradilova, et al.
International Journal of Cancer
|
December 18, 2010
Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity
Jakub Tomala, Helena Chmelova, Jiri Strohalm, et al.
Journal of Biomedical Nanotechnology
|
October 22, 2015
Novel IL-2-Poly(HPMA)Nanoconjugate Based Immunotherapy
Petra Votavova, Jakub Tomala, Vladimir Subr, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 38) with videos related to
Sort By:
Page
of 4
Oncoimmunology
|
May 4, 2016
IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?
Jakub Tomala, Marek Kovar
Methods in Molecular Biology (Clifton, N.J.)
|
January 15, 2020
Characterization of Immune Cell Subset Expansion in Response to Therapeutic Treatment in Mice
Jakub Tomala, Jamie B Spangler
Immunology Letters
|
February 12, 2014
Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera
Petra Votavova, Jakub Tomala, Marek Kovar
Journal of Immunology (Baltimore, Md. : 1950)
|
January 2, 2024
Engineering Anticytokine Antibodies for Immune Modulation
Jakub Tomala, Shanelle D Cao, Jamie B Spangler
Journal of Immunology (Baltimore, Md. : 1950)
|
October 6, 2009
In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy
Jakub Tomala, Helena Chmelova, Tomas Mrkvan, et al.
Cytokine
|
June 30, 2020
IL-7/αIL-7 mAb M25 immunocomplexes expand CD8<sup>+</sup> T cells but paradoxically abrogate the antitumor activity of CTLA-4 and PD-1 blockage
Dominik Hrabos, Tereza Hnizdilova, Jakub Tomala, et al.
Journal of Drug Targeting
|
October 11, 2011
Synergistic effect of EMF-BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma
Blanka Říhová, Tomáš Etrych, Milada Šírová, et al.
Oncoimmunology
|
June 23, 2017
Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells
Irena Adkins, Lenka Sadilkova, Nada Hradilova, et al.
International Journal of Cancer
|
December 18, 2010
Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity
Jakub Tomala, Helena Chmelova, Jiri Strohalm, et al.
Journal of Biomedical Nanotechnology
|
October 22, 2015
Novel IL-2-Poly(HPMA)Nanoconjugate Based Immunotherapy
Petra Votavova, Jakub Tomala, Vladimir Subr, et al.
Page
of 4